JP2016517888A5 - - Google Patents

Download PDF

Info

Publication number
JP2016517888A5
JP2016517888A5 JP2016512081A JP2016512081A JP2016517888A5 JP 2016517888 A5 JP2016517888 A5 JP 2016517888A5 JP 2016512081 A JP2016512081 A JP 2016512081A JP 2016512081 A JP2016512081 A JP 2016512081A JP 2016517888 A5 JP2016517888 A5 JP 2016517888A5
Authority
JP
Japan
Prior art keywords
compound
therapeutic agent
hydrogen
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016512081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016517888A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/036680 external-priority patent/WO2014179756A1/en
Publication of JP2016517888A publication Critical patent/JP2016517888A/ja
Publication of JP2016517888A5 publication Critical patent/JP2016517888A5/ja
Pending legal-status Critical Current

Links

JP2016512081A 2013-05-02 2014-05-02 骨選択的骨形成のオキシステロール骨標的薬剤 Pending JP2016517888A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361818825P 2013-05-02 2013-05-02
US61/818,825 2013-05-02
PCT/US2014/036680 WO2014179756A1 (en) 2013-05-02 2014-05-02 Bone-selective osteogenic oxysterol-bone targeting agents

Publications (2)

Publication Number Publication Date
JP2016517888A JP2016517888A (ja) 2016-06-20
JP2016517888A5 true JP2016517888A5 (enExample) 2017-06-15

Family

ID=51844004

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016512081A Pending JP2016517888A (ja) 2013-05-02 2014-05-02 骨選択的骨形成のオキシステロール骨標的薬剤

Country Status (7)

Country Link
US (1) US9683009B2 (enExample)
EP (1) EP2991652A4 (enExample)
JP (1) JP2016517888A (enExample)
CN (1) CN105263500A (enExample)
AU (1) AU2014259672A1 (enExample)
CA (1) CA2911205A1 (enExample)
WO (1) WO2014179756A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2643732C (en) 2006-02-27 2012-08-21 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
JP6262723B2 (ja) * 2012-05-07 2018-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ オキシステロールアナログｏｘｙ１３３は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する
AU2014259672A1 (en) 2013-05-02 2015-12-03 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
GB201319776D0 (en) * 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
CN107427526B (zh) 2014-12-09 2021-08-03 华沙整形外科股份有限公司 涉及甾醇的化合物和方法
US9877836B2 (en) 2015-07-10 2018-01-30 Warsaw Orthopedic, Inc. Compression resistant implants including an oxysterol and methods of use
US9878070B2 (en) 2015-06-17 2018-01-30 Warsaw Orthopedic, Inc. Malleable implants including an oxysterol and methods of use
US10632230B2 (en) 2015-07-10 2020-04-28 Warsaw Orthopedic, Inc. Implants having a high drug load of an oxysterol and methods of use
US9987289B2 (en) 2015-07-10 2018-06-05 Warsaw Orthopedic, Inc. Slow release oxysterols and methods of use
US12171909B2 (en) 2015-07-10 2024-12-24 Warsaw Orthopedic, Inc. Implants having a drug load of an oxysterol and methods of use
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
AU2016347052B2 (en) * 2015-10-27 2021-03-25 Warsaw Orthopedic, Inc. Implants having a drug load of an oxysterol and methods of use
US10688222B2 (en) * 2016-11-21 2020-06-23 Warsaw Orthopedic, Inc. Lyophilized moldable implants containing an oxysterol
US11384114B2 (en) 2016-12-09 2022-07-12 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
CN110392686A (zh) 2016-12-30 2019-10-29 频率治疗公司 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
US10294264B2 (en) * 2017-04-21 2019-05-21 Warsaw Orthopedic, Inc. Oxysterol-therapeutic agent derivative for bone healing
US10434106B2 (en) 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
US11464888B2 (en) 2017-06-12 2022-10-11 Warsaw Orthopedic, Inc. Moldable formulations containing an oxysterol in an acellular tissue matrix
KR102318505B1 (ko) * 2019-04-26 2021-10-27 서울대학교산학협력단 골 세포 전환 재조합 단백질 및 골 표적화 분자를 포함하는 골 특이적 복합체

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB869007A (en) 1956-10-03 1961-05-25 Ciba Ltd New heterocyclically substituted steroids
CH433275A (de) 1963-07-09 1967-04-15 Hoffmann La Roche Verfahren zur Herstellung von 19-Alkylsteroiden
JPS5111114B1 (enExample) 1969-03-14 1976-04-08
US3887545A (en) 1973-11-12 1975-06-03 Hoffmann La Roche Synthesis of 1{60 -hydroxylated cholesterol derivatives
US4264512A (en) 1975-09-29 1981-04-28 The Regents Of The University Of California 3-Deoxy-1α-hydroxy- and 3-deoxy-1α,25-dihydroxycholecalciferol and processes for the preparation thereof
US4183852A (en) 1977-07-18 1980-01-15 Kaiser Emil T Process for preparing 25-hydroxycholesterol
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4743597A (en) 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
LU87201A1 (fr) 1988-04-14 1989-11-14 Cird Complexes a base d'anthraline et d'un sterol,leur procede d'obtention et leur utilisation en therapeutique et cosmetique
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
GB9118465D0 (en) 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
US5203975A (en) 1991-10-29 1993-04-20 E. I. Du Pont De Nemours And Company Process for cathodic electrodeposition of a clear coating over a conductive paint layer
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
JPH09507741A (ja) 1992-06-10 1997-08-12 アメリカ合衆国 ヒト血清による不活性化に耐性のあるベクター粒子
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
DE69433592T2 (de) 1993-11-09 2005-02-10 Targeted Genetics Corp., Seattle Die erzielung hoher titer des rekombinanten aav-vektors
US7060450B1 (en) 1993-12-30 2006-06-13 President And Fellows Of Harvard College Screening assays for agonists and antagonists of the hedgehog signaling pathway
KR970700199A (ko) 1994-01-06 1997-01-08 에드워드 이. 데이비스 신규한 항남성호르몬제 및 이와 관련된 조성물 및 사용방법(novel antiandrogenic agents and related pharmaceutical compositions and methods of use)
JP2000511404A (ja) 1996-04-09 2000-09-05 ビー・テイー・ジー・インターナシヨナル・リミテツド 神経精神、免疫又は内分泌障害を治療するための７α置換ステロイドの使用
CA2251983C (en) 1996-04-19 2003-12-16 Sudhakar Kadiyala Regeneration and augmentation of bone using mesenchymal stem cells
US6893830B1 (en) 1996-09-27 2005-05-17 The Board Of Regents Of The University Of Texas System Method of screening oxysterol activation of LXRα
US5840752A (en) 1996-11-21 1998-11-24 Henry; James P. Reduction of hair growth
US6080779A (en) 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
US5855920A (en) 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
PL334840A1 (en) 1997-01-24 2000-03-27 Univ California Application of fxr, pparalpha and lxralpha activators in order to restore the barrier function, to stimulate epithelium differentation and to inhibit proliferation
TR199902793T2 (xx) 1997-05-16 2000-06-21 Akzo Nobel N.V. 20-Aralkil-5alfa-pregnan t�revleri.
DE19723794A1 (de) 1997-06-06 1998-12-10 Jenapharm Gmbh Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität
US5929062A (en) 1997-06-19 1999-07-27 University Of Western Ontario Oxysterol inhibition of dietary cholesterol uptake
WO1999000117A2 (en) 1997-06-27 1999-01-07 Ontogeny, Inc. Neuroprotective methods and reagents
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
AU2901199A (en) 1998-03-13 1999-09-27 Merck & Co., Inc. Methods of inhibiting bone resorption
EP0943332A1 (en) 1998-03-19 1999-09-22 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Prevention and treatment of adhesions
US6906069B1 (en) 1999-01-08 2005-06-14 Amgen Inc. LXR modulators
ES2188515T3 (es) 1999-03-09 2003-07-01 Akzo Nobel Nv Derivados de 22r-hidroxicolesta-8,14-dieno con actividad inhibidora de la meiosis.
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US6586189B2 (en) 1999-06-18 2003-07-01 City Of Hope Screening method for PPAR-γ ligands
AU1291901A (en) 1999-09-01 2001-03-26 University Of British Columbia, The Compositions and methods for modulating hdl cholesterol and triglyceride levels
WO2001094379A2 (en) 2000-06-08 2001-12-13 The Regents Of The University Of California Methods and compositions for controlled synthesis of amino acid polymers
US20020115695A1 (en) 2000-11-07 2002-08-22 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
GB0101933D0 (en) 2001-01-25 2001-03-07 Astrazeneca Ab Therapy
WO2002080244A2 (en) 2001-02-12 2002-10-10 Asm America, Inc. Improved process for deposition of semiconductor films
EP1401469A2 (en) 2001-04-09 2004-03-31 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
CN100430062C (zh) 2002-03-15 2008-11-05 萨马里坦药品公司 神经保护性螺甾烯醇药用组合物
EP1556057A4 (en) 2002-08-29 2009-07-15 Univ California MEDIUM AND METHOD FOR REINFORCING BONE TRAINING
DE10307104A1 (de) 2003-02-19 2004-09-23 Schering Ag Antitumor wirksame 2-substituierte Estra-1,3,5(10)-trien-3-yl sulfamate
NZ545087A (en) 2003-07-09 2009-10-30 Forbes Medi Tech Inc Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions
WO2005028616A2 (en) 2003-07-24 2005-03-31 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Morphogen compositions and methods of use thereof to treat heart disorders
AU2004267067A1 (en) 2003-08-18 2005-03-03 Wyeth Human LXR alpha variants
WO2005020928A2 (en) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
WO2005065315A2 (en) 2003-12-24 2005-07-21 University Of Louisville Research Foundation Bone targeting compounds for delivering agents to the bone for interaction therewith
EP1758919A1 (en) 2004-06-10 2007-03-07 Merck & Co., Inc. Estrogen receptor modulators
WO2006012902A2 (en) 2004-08-02 2006-02-09 Novozymes A/S Creation of diversity in polypeptides
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
WO2006110490A2 (en) 2005-04-07 2006-10-19 The Regents Of The University Of California Agents and methods for osteogenic oxysterols inhibition of oxidative stress on osteogenic cellular differentiation
CN104017083A (zh) 2005-04-15 2014-09-03 亚利桑那癌症治疗公司 用于治疗转移性癌症的治疗肽
EP1931353A4 (en) 2005-09-02 2009-07-29 Univ California OSTEOGENIC AND ANTI-ADIOGENIC OXYSTEROLS
CA2643732C (en) 2006-02-27 2012-08-21 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
US20100048944A1 (en) 2006-07-19 2010-02-25 Farhad Parhami Interactions of hedgehog and liver x receptor signaling pathways
US20080070883A1 (en) 2006-09-19 2008-03-20 Wyeth Use of LXR modulators for the prevention and treatment of skin aging
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
WO2008082520A2 (en) 2006-12-19 2008-07-10 The Regents Of The University Of California Inhibition of ppar gamma expression by specific osteogenic oxysterols
JP2010521423A (ja) * 2007-02-23 2010-06-24 ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション，インコーポレーテッド 骨と相互作用するために、骨へ作用剤を標的輸送するための方法および化合物
WO2008109780A1 (en) * 2007-03-06 2008-09-12 University Of Louisville Research Foundation, Inc Methods and compounds for the targeted delivery of agents to bone for interaction therewith
WO2008115469A2 (en) 2007-03-16 2008-09-25 The Regents Of The University Of California Role of hedgehog signaling in atherosclerosis and cardiovascular disease
CA2707663C (en) * 2007-12-03 2017-05-30 The Regents Of The University Of California Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
MY163799A (en) 2008-02-07 2017-10-24 Dsg Tech Holdings Limited Method of making an absorbent composite and absorbent articles employing the same
WO2011006087A1 (en) 2009-07-10 2011-01-13 The Regents Of The University Of California Inhibition of ppar gamma expression in preadipocyte cells by oxysterols
US20120309730A1 (en) 2010-02-16 2012-12-06 The Johns Hopkins University Oxysterols that activate liver x receptor signaling and inhibit hedgehog signaling
WO2012024584A2 (en) * 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024581A2 (en) * 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
WO2012024583A2 (en) * 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Oxysterol compounds
JP6262723B2 (ja) * 2012-05-07 2018-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ オキシステロールアナログｏｘｙ１３３は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する
EP2847205A4 (en) * 2012-05-07 2016-01-20 Univ California NOVEL OXYSTEROL ANALOGUE OXY149 FOR THE INDUCTION OF OSTEOGENESIS AND HEDGEHOG SIGNAL PATH AND THE INHIBITION OF ADIPOGENESIS
AU2014259672A1 (en) 2013-05-02 2015-12-03 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
JP6530056B2 (ja) 2014-05-02 2019-06-12 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 骨選択的骨形成オキシステロールビスホスホネート類似体

Similar Documents

Publication Publication Date Title
JP2016517888A5 (enExample)
Giger et al. Biomedical applications of bisphosphonates
JP2012255026A5 (enExample)
MX2013006591A (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
JP2015500225A5 (enExample)
HK1205156A1 (en) Cyclodextrin-based polymers for therapeutic delivery
JP2015511609A5 (enExample)
JP2012136540A5 (enExample)
JP2011102304A5 (enExample)
WO2015042078A3 (en) Substituted aminopyrimidine compounds and methods of use
IN2012DN06720A (enExample)
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP2014508752A5 (enExample)
JP2015524444A5 (enExample)
JP2015532296A5 (enExample)
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
JP2017501140A5 (enExample)
WO2016210376A3 (en) Therapeutic peptides and methods of use thereof
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MY160652A (en) Pharmaceutical composition for oral administration
JP2013541583A5 (enExample)
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
JP2015516419A5 (enExample)